跳转至内容
Merck
CN

Uridylation by TUT4/7 Restricts Retrotransposition of Human LINE-1s.

Cell (2018-08-21)
Zbigniew Warkocki, Paweł S Krawczyk, Dorota Adamska, Krystian Bijata, Jose L Garcia-Perez, Andrzej Dziembowski
摘要

LINE-1 retrotransposition is tightly restricted by layers of regulatory control, with epigenetic pathways being the best characterized. Looking at post-transcriptional regulation, we now show that LINE-1 mRNA 3' ends are pervasively uridylated in various human cellular models and in mouse testes. TUT4 and TUT7 uridyltransferases catalyze the modification and function in cooperation with the helicase/RNPase MOV10 to counteract the RNA chaperone activity of the L1-ORF1p retrotransposon protein. Uridylation potently restricts LINE-1 retrotransposition by a multilayer mechanism depending on differential subcellular localization of the uridyltransferases. We propose that uridine residues added by TUT7 in the cytoplasm inhibit initiation of reverse transcription of LINE-1 mRNAs once they are reimported to the nucleus, whereas uridylation by TUT4, which is enriched in cytoplasmic foci, destabilizes mRNAs. These results provide a model for the post-transcriptional restriction of LINE-1, revealing a key physiological role for TUT4/7-mediated uridylation in maintaining genome stability.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗-FLAG® M2 小鼠抗, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
PerfectHyb Plus杂交缓冲液, for Northern and Southern blotting, solution
Sigma-Aldrich
抗γ-微管蛋白抗体,小鼠单克隆 小鼠抗, clone GTU-88, ascites fluid
Sigma-Aldrich
单克隆抗-FLAG®, clone SIG1-25, ascites fluid
Sigma-Aldrich
麦芽糖 溶液, for molecular biology, BioReagent, ~20% in H2O
Sigma-Aldrich
抗蛋白H4抗体,pan,克隆62-141-13,兔单克隆, clone 62-141-13, Upstate®, from rabbit
Sigma-Aldrich
Anti-ZCCHC6 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab2
Sigma-Aldrich
MISSION® esiRNA, targeting human ZCCHC11